Methotrexate (MTX) use in “typical” cases.
| Case | Respondents Indicating They Would Use MTX, n (%) | Dosage*, n (%) | Route of Administration, n (%) |
|---|---|---|---|
| Mild | 22/29 (76) | Low 3 (14) | Oral 5 (23) |
| Med 9 (41) | SC 15 (68) | ||
| High 10 (45) | IV 2 (9) | ||
| Moderate | 104/124 (84) | Low 11 (11) | Oral 17 (16) |
| Med 51 (49) | SC 66 (63) | ||
| High 42 (40) | IV 6 (6) | ||
| > 1 option 15 (14) | |||
| Severe | 27/34 (79) | Low 1 (4) | Oral 4 (15) |
| Med 12 (44) | SC 17 (63) | ||
| High 14 (52) | IV 4 (15) | ||
| IM 1 (4) | |||
| > 1 option 1 (4) | |||
| Ulcerative | 38/57 (67) | Low 4 (11) | Oral 2 (5) |
| Medium 10 (26) | SC 21 (55) | ||
| High 19 (50) | IV 6 (16) | ||
| Did not respond 5 (13) | > 1 option 4 (11) | ||
| Did not respond 5 (13) |
↵* Low: ≤ 10 mg/m2/week; Med: > 10 mg < 20 mg/m2/week; High: ≥ 20 mg/m2/week. SC: subcutaneous; IV: intravenous; IM: intramuscular.